Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel

Introduction Recently, paclitaxel has joined doxorubicin as one of the most active single agents for the treatment of metastatic breast cancer (1,2). Because these drugs now appear to be non-cross-resistant, combinations have been studied using various doses and schedules to assess efficacy and toxi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer investigation 1998, Vol.16 (2), p.67-71
Main Authors: Hudis, Clifford, Riccio, Louise, Seidman, Andrew, Baselga, Jose, Currie, Violante, Fennelly, David, Gilewski, Teresa, Lebwohl, David, Moynahan, Maryellen, Raptis, George, Surbone, Antonella, Sklarin, Nancy, Yao, T. J., Keefe, Deborah, Norton, Larry
Format: Article
Language:English
Subjects:
Adult
Antineoplastic agents
Biological and medical sciences
Breast Neoplasms - drug therapy
Chemotherapy
Doxorubicin - administration & dosage
Doxorubicin - adverse effects
Drug Administration Schedule
Heart - drug effects
Heart Failure - chemically induced
Heart Failure - diagnosis
Humans
Medical sciences
Middle Aged
Paclitaxel - administration & dosage
Paclitaxel - adverse effects
Pharmacology. Drug treatments
Risk Factors
Stroke Volume
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Recently, paclitaxel has joined doxorubicin as one of the most active single agents for the treatment of metastatic breast cancer (1,2). Because these drugs now appear to be non-cross-resistant, combinations have been studied using various doses and schedules to assess efficacy and toxicity (3-7). However, concurrent administration of the two drugs at full doses has been associated with increased toxicity. In particular, an increased incidence of congestive heart failure has been seen in two studies of doxorubicin plus concurrent paclitaxel (6,7). At our institution, we have been developing "dose-dense" chemotherapy applying doxorubicin, paclitaxel, and cyclophosphamide as adjuvant treatment for high-risk primary breast cancer. To minimize toxicity and maximize delivered dose intensity, these drugs are given sequentially in the above order rather than concurrently. Because of the suggestion that the use of doxorubicin and paclitaxel might increase the risk of cardiac toxicity, we reviewed our prospective nonrandomized phase II study of sequential doxorubicin and paclitaxel to determine the incidence of cardiotoxicity.
ISSN:0735-7907
1532-4192
DOI:10.3109/07357909809039759